Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EXPAREL 20 mL Clear all
Terminated Early Phase 1 Interventional

Multimodal Pain Management Following Primary TKA

NCT02369523
View directory record Official record
Conditions
Pain
Interventions
Exparel, Ropivacaine cocktail (PIC), Bupivacaine
Drug
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 2, 2026, 7:51 PM EDT
Suspended Phase 4 Interventional

Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion

NCT03745040
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Spondylolisthesis
Interventions
Liposomal bupivacaine
Drug
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 1 Interventional Results available

Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients

NCT05537883
View directory record Official record
Conditions
Morbid Obesity, Bariatric Surgery Candidate
Interventions
Liposomal bupivacaine, Bupivacaine Injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 2, 2026, 7:51 PM EDT
Withdrawn Phase 3 Interventional

Liposomal Bupivacaine in Shoulder Arthroscopy

NCT04461028
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Liposomal bupivacaine, Bupivacaine with Dexamethasone Solution
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 1 Interventional

PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery

NCT02985762
View directory record Official record
Conditions
Spinal Fusion, Pain Management
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 2, 2026, 7:51 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section

NCT02847013
View directory record Official record
Conditions
Pain
Interventions
TAP block w Liposomal bupivacaine, TAP block w normal saline
Drug · Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 2, 2026, 7:51 PM EDT
Enrolling by invitation Phase 4 Interventional

Pilot Study on EXPAREL as an Intra-articular Posteromedial Surgeon Administered (IPSA) Block vs. Local Infiltration Analgesia in Knee Replacement Surgery

NCT07584915
View directory record Official record
Conditions
Total Knee Arthroplasty, Total Knee Arthroplasty Recovery
Interventions
Intra-articular Posteromedial Surgeon Administered (IPSA) Block with LIA, Local Infiltration Analgesia (LIA), Bupivacaine liposome injectable suspension (IPSA block), Bupivacaine liposome injectable suspension (LIA)
Procedure · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

NCT01683071
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 2, 2026, 7:51 PM EDT
Terminated Phase 1 Interventional

Study in Adult Subjects Undergoing Posterolateral Thoracotomy

NCT03428984
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 2, 2026, 7:51 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion

NCT06350981
View directory record Official record
Conditions
Back Pain, Surgery-Complications, Narcotic Use, Physical Stress, Post Operative Pain
Interventions
Exparel, Bupivacain
Drug
Lead sponsor
Foundation for Orthopaedic Research and Education
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

NCT02713178
View directory record Official record
Conditions
Pain
Interventions
bupivacaine liposome injectable suspension, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 2, 2026, 7:51 PM EDT
Not yet recruiting Not applicable Interventional

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

NCT07254650
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 2, 2026, 7:51 PM EDT
Recruiting No phase listed Observational

Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block

NCT04209504
View directory record Official record
Conditions
Shoulder Surgery, Shoulder Pain, Shoulder Injuries, Shoulder Arthritis, Shoulder Disease, Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Arthropathy of Left Shoulder, Rotator Cuff Arthropathy of Right Shoulder, Rotator Cuff Repair
Interventions
Ultrasound, Ropivacaine, Bupivacaine, MediPines AGM100 Advanced Respiratory Monitoring System
Diagnostic Test · Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty

NCT02255500
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine FNB, EXPAREL Infiltration
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Not applicable Interventional

Prospective RCT Comparing Perioperative Pain

NCT03253198
View directory record Official record
Conditions
Arthroplasty Shoulder
Interventions
Saline, Bupivacaine liposome
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

ESP Block VS TAP in Laparoscopic Hysterectomy

NCT04003987
View directory record Official record
Conditions
Hysterectomy
Interventions
Liposomal bupivacaine, bupivacaine, 0.125%
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 2, 2026, 7:51 PM EDT
Not listed Phase 2 Interventional

Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo

NCT03504865
View directory record Official record
Conditions
Mastectomy, Breast Cancer
Interventions
Liposomal bupivacaine, Standard bupivacaine, Placebo
Drug · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery

NCT02713230
View directory record Official record
Conditions
Pain
Interventions
bupivacaine liposome injectable suspension, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Mobile, Alabama • Englewood, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy

NCT04300231
View directory record Official record
Conditions
Cystectomy
Interventions
epidural bupivacaine 0.05%, Liposomal bupivacaine, bupivacaine 0.125%, bupivacaine 0.5%, /hydromorphone 0.05mg/ml, injectable saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

Erector Spinae Block Versus Surgeon Infiltration in VATS Procedures

NCT03859635
View directory record Official record
Conditions
Pain, Postoperative, Thoracic, Acute Pain
Interventions
Liposomal Bupivacaine, Bupivacaine, 0.25%, Bupivacaine, 0.5%
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 2, 2026, 7:51 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine injection, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

QL Block With Exparel in Colectomy

NCT03827291
View directory record Official record
Conditions
Laparotomy, Colectomy
Interventions
Exparel, Thoracic epidural analgesia
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 2, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

NCT03913091
View directory record Official record
Conditions
Shoulder Pain
Interventions
Liposomal Bupivacaine, 0.5% Bupivacaine HCL
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 2, 2026, 7:51 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients

NCT05900427
View directory record Official record
Conditions
Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty
Interventions
Liposomal bupivacaine, Bupivacaine
Drug
Lead sponsor
Johnny K. Lee
Other
Eligibility
18 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 7:51 PM EDT